UGT1*1 genotyping in a Canadian Inuit population

Pharmacogenetics

Volumn 7, Issue 2, 1997, Pages 153-156

  Monaghan, Gemma ^a   Foster, Brian ^b   Jurima Romet, Malle ^b   Hume, Robert ^a   Burchell, Brian ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Life Sciences Division   (Canada)

Author keywords

Genotyping; Gilbert's syndrome; Inuit; UGT1*1 gene promoter

Indexed keywords

ETHINYLESTRADIOL; PARACETAMOL; BILIRUBIN; GLUCURONOSYLTRANSFERASE;

ALLELE; ARTICLE; CANADA; CORONARY ARTERY DISEASE; DIET; DRUG HYPERSENSITIVITY; DRUG METABOLISM; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; GILBERT DISEASE; HEMOLYSIS; HUMAN; HYPERBILIRUBINEMIA; JAUNDICE; PRIORITY JOURNAL; ASIAN; CAUCASIAN; ESKIMO; ETHNOLOGY; GENETICS; METABOLISM; PROMOTER REGION; UNITED KINGDOM;

ASIAN CONTINENTAL ANCESTRY GROUP; BILIRUBIN; CANADA; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; GILBERT DISEASE; GLUCURONOSYLTRANSFERASE; HUMANS; INUITS; PROMOTER REGIONS (GENETICS); SCOTLAND;

EID: 0030610807     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199704000-00010     Document Type: Article

References (15)

1. Bosma PJ, Roy Chowdhury J, Bakker C, Gantla S, De Boer A, Oostra BA, Lindhout D, Tytgat GNJ, Jansen PLM, Oude Elferink RPJ, Roy Chowdhury N. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome. N Engl J Med 1995: 333, 1171-75.
2. Carulli N, Ponz De Leon M, Mauro E, Manenti F, Ferrari A. Alteration of drug metabolism in Gilbert's syndrome. Gut 1976: 17, 581-587.
3. De Morais SMF, Uetrecht JP, Wells PG. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. Gastroenterology. 1992: 102, 577-586.
4. Douglas AP, Savage RL, Rawlins MD. Paracetamol (acetominophen) kinetics in patients with Gilbert's syndrome. Europ J Clin Pharmacol 1978: 13, 209-212.
5. Ebner T, Remmel RP, Burchell B. Human bilirubin UDP-glucuronosyltransferase catalyses the glucoronidation of ethinylestradiol. Molec Pharmacol 1993: 43, 649-654.
6. Jurima-Romet M, Goldstein JA, LeBelle M, Aubin RA, Foster BC, Walop W, Rode A. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. Pharmacogenetics. 1996: 6, 329-339.
7. Jurima-Romet M, Foster BC, Rode A, Casley WL, Vloshinsky P, Huang HS, Geertsen S. CYP2D6-related oxidation polymorphism in a Canadian Inuit population. Can J Physiol Pharmacol 1997 (in press).
8. Kreek MJ, Weser E, Sleisenger MH, Jeffries GH. Idiopathic cholestasis of pregnancy: the response to challenge with the synthetic estrogen, ethinylestrdiol. N Engl J Med 1967: 277, 1391-1399.
9. Kromann N, Christiansen J, Flachs H, Dam M, Hvidberg EF. Differences in single dose phenytoin kinetics between Greenland Eskimos and Danes. Ther Drug Monit 1981: 3, 239-245.
10. Macklon AF, Savage RL, Rawlins MD. Gilbert's syndrome and drug metabolism. Clin Pharmacokinet 1979: 4, 223-232.
11. McAlpine PJ, Chen S-H, Cox DW, Dossetor JB, Giblett E, Steinberg AG, Simpson NE. Genetic markers in blood in a Canadian Eskimo population with a comparison of allele frequencies in circumpolar populations. Human Hered 1974: 24, 114-142.
12. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996: 347, 578-581.
13. Schaefer O. Adverse reactions to drugs and metabolic problems perceived in Northern Canadian Indians and Eskimos. In: Kalow W, Goedde H, Agarwa DP, eds. Ethnic differences in reactions to drugs and xenobiotics. New York, Alan R Liss Inc. 1986: 77-83.
14. Schwertner HA, Jackson WG, Tolan G. Association of low serum bilirubin with increased risk of coronary artery disease. Clin Chem 1994: 40, 18-23.
15. Ullrich D, Sieg A, Blume R, Bock KW, Schroter W and Bircher J. Normal pathways for glucuronidation, sulphation and oxidation of paracetamol in Gilbert's syndrome. Eur J Clin Invest 1987; 17, 237-240